Compare
Abbott Laboratories vs TransMedics Group (ABT vs TMDX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and TransMedics Group (TMDX) -29.1%; so far this year the figures are -12.3% and -27.5%.
Abbott Laboratories is the larger company by market value, about 62.2 times the size of TransMedics Group.
On trailing earnings, ABT trades at 40.9 times and TMDX at 24.1 times.
Revenue grew +10.0% at ABT and +28.5% at TMDX over the last year.
ABT yields 2.29%. TMDX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | TMDX | |
|---|---|---|
| Price | $109.93 | $88.24 |
| 1-day | -3.23% | +27.92% |
| YTD | -12.26% | -27.46% |
| 1 year | -11.73% | -29.10% |
| 3 years | +15.70% | +131.91% |
| Market cap | $190.4B | $3.1B |
| P/E | 40.9 | 24.1 |
| P/S | 3.95 | 4.21 |
| P/B | 3.73 | 5.57 |
| Revenue growth | +10.00% | +28.50% |
| EPS growth | -66.20% | +47.60% |
| Gross margin % | 56.9 | 58.6 |
| Net margin % | 9.7 | 19.9 |
| ROE % | 9.2 | 26.2 |
| Debt / equity | 0.61 | 0.21 |
| FCF yield % | 3.5 | 1.5 |
| Dividend yield % | 2.29 | — |
| Beta | 0.06 | 1.17 |
| RSI (14) | 58.5 | 66.6 |
| Technical rating |